LY96 and colorectal carcinoma: Here, we successfully prepared endotoxin-free sTLR4/MD-2 complex which competed with cellular membrane TLR4 by targeting LPS and then suppressed human CRC in vitro and in vivo, raising the possibility of a new prevention agent against CRC.